Early Human Development
Volume 86, Issue 5 , Pages 315-317 , May 2010

Effect of ibuprofen on bilirubin–albumin binding in vitro at concentrations observed during treatment of patent ductus arteriosus

  • Diot C.

      Affiliations

    • SGS Cephac Europe, Saint-Benoît Cedex, France
    • ,
  • Kibleur Y.

      Affiliations

    • Orphan Europe, Paris, France
    • ,
  • Desfrere L.

      Affiliations

    • Service de Néonatologie, Hôpital Louis Mourier, AP HP, Colombes, Université Paris 7, Faculté de Médecine Denis Diderot, Paris, France
    • Corresponding Author InformationCorresponding author. Hôpital Louis Mourier, 178 rue des Renouillers, 92700 Colombes, France. Tel.: +33 1 47 60 61 62; fax: +33 1 47 60 61 31.

Received 19 February 2010 ,Revised 19 April 2010 ,Accepted 20 April 2010.

References 

  1. Mosca F, Bray M, Lattanzio M, Fumagalli M, Tosetto C. Comparative evaluation of the effects of indomethacin and ibuprofen on cerebral perfusion and oxygenation in preterm infants with patent ductus arteriosus. J Pediatr. 1997;131(4):549–554
  2. Pezzati M, Vangi V, Biagiotti R, Bertini G, Cianciulli D, Rubaltelli FF. Effects of indomethacin and ibuprofen on mesenteric and renal blood flow in preterm infants with patent ductus arteriosus. J Pediatr. 1999;135(6):733–738
  3. Cooper-Peel C, Brodersen R, Robertson A. Does ibuprofen affect bilirubin–albumin binding in newborn infant serum?. Pharmacol Toxicol. 1996;79(6):297–299
  4. Honore B, Brodersen R. Albumin binding of anti-inflammatory drugs. Utility of a site-oriented versus a stoichiometric analysis. Mol Pharmacol. 1984;25(1):137–150
  5. Ahlfors CE. Effect of ibuprofen on bilirubin–albumin binding. J Pediatr. 2004;144(3):386–388
  6. Aranda JV, Clyman R, Cox B, Van Overmeire B, Wozniak P, Sosenko I, et al. A randomized, double-blind, placebo-controlled trial on intravenous ibuprofen l-lysine for the early closure of nonsymptomatic patent ductus arteriosus within 72hours of birth in extremely low-birth-weight infants. Am J Perinatol. 2009;26(3):235–245
  7. Desfrere L, Zohar S, Morville P, Brunhes A, Chevret S, Pons G, et al. Dose-finding study of ibuprofen in patent ductus arteriosus using the continual reassessment method. J Clin Pharm Ther. 2005;30(2):121–132
  8. Gregoire N, Gualano V, Geneteau A, Millerioux L, Brault M, Mignot A, et al. Population pharmacokinetics of ibuprofen enantiomers in very premature neonates. J Clin Pharmacol. 2004;44(10):1114–1124
  9. Van Overmeire B, Touw D, Schepens PJ, Kearns GL, van den Anker JN. Ibuprofen pharmacokinetics in preterm infants with patent ductus arteriosus. Clin Pharmacol Ther. 2001;70(4):336–343
  10. Gournay V, Roze JC, Kuster A, Daoud P, Cambonie G, Hascoet JM, et al. Prophylactic ibuprofen versus placebo in very premature infants: a randomised, double-blind, placebo-controlled trial. Lancet. 2004;364(9449):1939–1944
  11. Desfrere L, Mourdie J, Barbier A, Moriette G. Effect of ibuprofen on unbound bilirubin levels in preterm newborns, [Absract]. In: PAS Annual Meeting 2007. 2007;8447.11
  12. Ahlfors CE. Measurement of unbound bilirubin by the peroxidase test using zone fluidics. Chim Clin Acta. 2006;365:78–85
  13. Ahlfors CE, Vreman H, Wrong R, Bender G, Oh W, Morris B, et al. Effect of sample dilution, peroxidase concentration, and chloride ion on the measurement of unbound bilirubin in premature newborns. Clin Biochem. 2007;40(3–4):261–267
  14. Ahlfors CE. Unbound bilirubin associated with kernicterus: a historical approach. J Pediatr. 2000;137(4):540–544
  15. Brodersen R. Competitive binding of bilirubin and drugs to human serum albumin studied by enzymatic oxidation. J Clin Invest. 1974;54(6):1353–1364
  16. Odell G, Storey G, Rosenberg L. Studies in kernicterus.3. The saturation of serum proteins with bilirubin during neonatal life and its relationship to brain damage at five years. J Pediatr. 1970;76(1):12–21
  17. Ambat MT, Ostrea EM, Aranda JV. Effect of ibuprofen l-lysinate on bilirubin binding to albumin as measured by saturation index and horseradish peroxidase assays. J Perinatol. 2008;28(4):287–290
  18. Van Overmeire B, Vanhagendoren S, Schepens PJ, Ahlfors CE. Abstract. Pediatr Res. 2004;2687
  19. Rheinlaender C, Helfenstein D, Walch E, Berns M, Obladen M, Koehne P. Total serum bilirubin levels during cyclooxygenase inhibitor treatment for patent ductus arteriosus in preterm infants. Acta Paediatr. 2009;98(1):36–42
  20. Zecca E, Romagnoli C, De Carolis M, Costa S, Marra R, De Luca D. Does ibuprofen increase neonatal hyperbilirubinemia?. Pediatrics. 2009;124(2):480–484
  21. Aranda JV, Varvarigou A, Beharry K, Bansal R, Bardin C, Modanlou H, et al. Pharmacokinetics and protein binding of intravenous ibuprofen in the premature newborn infant. Acta Paediatr. 1997;86(3):289–293
  22. Ahlfors CE. Benzyl alcohol, kernicterus, and unbound bilirubin. J Pediatr. 2001;139(2):317–319
  23. Hirt D, Van Overmeire B, Treluyer JM, Langhendries JP, Marguglio A, Eisinger MJ, et al. An optimized ibuprofen dosing scheme for preterm neonates with patent ductus arteriosus, based on a population pharmacokinetic and pharmacodynamic study. Br J Clin Pharmacol. 2008;65(5):629–636

PII: S0378-3782(10)00089-7

doi: 10.1016/j.earlhumdev.2010.04.006

Early Human Development
Volume 86, Issue 5 , Pages 315-317 , May 2010

Article Tools

* Image Usage & Resolution